about
Expression of DNA methyltransferase (Dnmt1) in testicular germ cells during development of mouse embryoCharacterization of 11-dehydro-thromboxane B2 recombinant antibody obtained by phage display technology.Design, production, and characterization of recombinant neocarzinostatin apoprotein in Escherichia coli.Characterization of a Shiga toxin 1-neutralizing recombinant Fab fragment isolated by phage display system.Recombinant human monoclonal Fab fragments against rotavirus from phage display combinatorial libraries.[Development of diagnostically and therapeutically useful human antibody medicines by phage display system].Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen.Identification of cell proliferation-associated epitope on CD98 oncoprotein using phage display random peptide library.Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein.Conformational change in transfer RNA is an early indicator of acute cellular damageGenetic polymorphism of C452T (T127I) in human gamma-glutamyl hydrolase in a Japanese population.Identification of anti-CD98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization.Immuno-Northern Blotting: Detection of RNA Modifications by Using Antibodies against Modified Nucleosides.Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection.Generation of a recombinant single-chain variable fragment (scFv) targeting 5-methyl-2'-deoxycytidine.Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study.Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population.Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.Facile and rapid high-performance liquid chromatography method for simultaneous determination of allopurinol and oxypurinol in human serum.Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.Bladder endothelin-1 receptor binding of bosentan and ambrisentan.Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin.Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis.Risk factors for hyperammonemia in pediatric patients with epilepsy.Influence of Genetic Polymorphisms and Concomitant Anxiolytic Doses on Antidepressant Maintenance Doses in Japanese Patients with Depression.Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.Human recombinant Fab fragment from combinatorial libraries of a B-cell lymphoma patient recognizes core protein of chondroitin sulphate proteoglycan 4.A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype.Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients.Phage display cloning and characterization of monoclonal antibody genes and recombinant Fab fragment against the CD98 oncoprotein.Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin.Genotype distributions and allele frequencies of possible major depressive disorder-associated single nucleotide polymorphisms, cyclic adenosine monophosphate response element binding protein 1 rs4675690 and Piccolo rs2522833, in a Japanese populatiBioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification.Augmented Renal Clearance in Pediatric Patients With Febrile Neutropenia Associated With Vancomycin Clearance.Application of fluorescence polarization immunoassay for determination of methotrexate-polyglutamates in rheumatoid arthritis patients.Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
P50
Q28512253-D0747772-B0E8-4516-B3E6-98D2172CB21AQ30894670-64D84357-A672-4D5D-AACE-3BA711D630E8Q31050361-ED365B90-91E1-4D13-A975-72391C34BC51Q31105407-2BA3562F-9BEA-422A-A42E-960263653DD0Q31937856-0552610B-570F-41BE-94B5-E6340F5B2D81Q33268136-FDF75EDF-848B-4D50-A1AA-294D71B536A8Q33271639-9EF09843-F379-4D1B-B88A-4B2028BBBBB1Q33294769-FAA5B251-C644-431F-8BAD-90348ECC7B2AQ33385489-80388E3A-3645-4D2B-AF90-30E2D38C2D3AQ34260059-60925BC4-A46C-462C-AA6E-E8E5894EB0E1Q34616048-1C88B6DA-C6FC-4D46-9335-C249CC67DA79Q35051389-BC3A2182-6B23-420C-AD99-BF9683E24803Q35852523-8D852937-FCF2-478D-A9B6-257BC8C59EA5Q36813019-5C4FB89E-A105-4900-A3CF-C6766B18CA86Q39789691-CDF524BB-9542-44A1-A4D3-A17A37731532Q41484971-E31FBE78-E460-49A8-A9B6-97F1A4E1E23EQ42702360-57386E18-1CB3-4371-A2CD-62DA65BC73B0Q42909845-793625FD-3931-4791-BC23-0AF0D35F8474Q43678180-229CEF1E-7D45-41CB-84FA-B71A87F4971EQ43870679-05949158-DBE6-4DB1-BFB7-186128E12836Q44209354-DB1F8886-C879-454B-85D7-2CAB4D048FA6Q44471259-8F1FFE41-53A5-4728-B071-9D629843935BQ45036983-D526026C-3C8B-494F-9132-FAF5BB9F44E7Q45762967-54F80A3F-CBE5-4A80-8712-E1D6EEAF0DC4Q45857175-FED0640C-9BA1-4023-A891-B3EE32C1F8AFQ45974894-77FEE238-2AAA-45CE-8C92-97F25FA90546Q46090014-731E380B-6B95-4237-86BC-6CAB10662101Q46921686-3051E2CF-6E35-4AB2-8F35-70458E591D79Q47418280-FA3BC38F-B2B1-4930-9FA0-F49C2A185DB2Q47572599-4A31A3C6-4EA8-46D5-B831-FCCAE76E719AQ47646643-5E55B5B6-ADF3-499E-8168-A071A69E80F8Q47849470-724E746B-99AF-4DAD-A758-E7000D2D7977Q48190053-E80D912D-5F45-4BA2-BC93-092910DD8946Q48328275-DC0BF237-12A5-463C-9913-4298835A4569Q48493597-638F7386-38EE-46A1-817C-390D9BC49542Q48740288-369A5FB5-42DB-4EB6-8B6B-4382E91C5C9AQ50222758-4ACC7DDC-A4B3-48E2-9C32-B4E0833206DCQ50647721-1EC004D4-A322-42D3-9272-8D42471253A2Q50647786-B9004343-A44A-482B-B1FD-FA34C594BB59Q50659752-A37293CF-5765-4897-B6B4-331D04F81FCA
P50
description
pharmaceutical researcher
@en
name
K Itoh
@ast
K Itoh
@nl
Kunihiko Itoh
@en
type
label
K Itoh
@ast
K Itoh
@nl
Kunihiko Itoh
@en
prefLabel
K Itoh
@ast
K Itoh
@nl
Kunihiko Itoh
@en
P106
P31
P496
0000-0003-4436-0529